ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

June 25, 2004

Obituary: NCI’s Elaine Ron, Expert in Radiation Heath Effects

December 3, 2010

Provenge Prolonged Prostate Cancer Survival By Seven Months, Study Finds

September 26, 2003

USPSTF’s Michael LeFevre: Lung Screening Can Save More Lives With Fewer Screens Than Mammography

August 2, 2013

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

LeMaistre To Retire As M.D. Anderson President In 1996

August 18, 1995